Dated: September 24, 2003.

Bruce G. Gellin,

Director, National Vaccine Program Office and Executive Secretary, National Vaccine Advisory Committee.

[FR Doc. 03–24797 Filed 9–29–03; 8:45 am]

BILLING CODE 4150-28-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

Citizens Advisory Committee on Public Health Service (PHS) Activities and Research at Department of Energy (DOE) Sites: Oak Ridge Reservation Health Effects Subcommittee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Agency for Toxic Substances and Disease Registry (ATSDR) and the Centers for Disease Control and Prevention (CDC) announce the following meeting.

Name: Citizens Advisory Committee on PHS Activities and Research at DOE Sites: Oak Ridge Reservation Health Effects Subcommittee (ORRHES).

Time and Date: 12 (noon)-8 p.m., October 21, 2003.

Place: DOE Information Center, 475 Oak Ridge Turnpike, Oak Ridge, Tennessee 37830. Telephone: (865) 241–4780.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Background: A Memorandum of Understanding (MOU) was signed in October 1990 and renewed in September 2000 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or "Superfund"). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

In addition, under an MOU signed in December 1990 with DOE and replaced by an MOU signed in 2000, the Department of Health and Human Services (HHS) has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production and use. HHS has delegated program responsibility to CDC.

Purpose: This subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, pertaining to CDC's and ATSDR's public health activities and research at this DOE site. Activities shall focus on providing the public with a vehicle to express concerns and provide advice and recommendations to CDC and ATSDR. The purpose of this meeting is to receive updates from ATSDR and CDC, and to address other issues and topics, as necessary.

Matters To Be Discussed: The agenda includes a discussion of the final Public Health Assessment on Uranium Release from the Y–12 plant, plan for addressing the Public Health Assessment on Iodine, description of cancer incidence review document, updates from the Public Health Assessment, Public Health Needs Assessment, Agenda, and Outreach and Communications Workgroup.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Lorine Spencer, Designated Federal Official, or Marilyn Palmer, Committee Management Specialist, Division of Health Assessment and Consultation, ATSDR, 1600 Clifton Road, NE., M/S E–32, Atlanta, Georgia 30333, telephone 1–888–42–ATSDR (28737), fax 404/498–1744.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and ATSDR.

Dated: September 24, 2003.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 03–24677 Filed 9–29–03; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Breast and Cervical Cancer Early Detection and Control Advisory Committee

In accordance with section 10(a)(2)of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Breast and Cervical Cancer Early Detection and Control Advisory Committee (BCCEDCAC).

Times and Dates:

9 a.m.–5 p.m., November 5, 2003. 9 a.m.–3 p.m., November 6, 2003.

Place: The Ritz-Carlton Buckhead, 3434 Peachtree Road, NE., Atlanta, Georgia 30326, Telephone: 404–237–2700.

Status: Open to the public, limited only by the space available.

Purpose: The committee is charged with advising the Secretary, Department of Health and Human Services, and the Director, CDC, regarding the early detection and control of breast and cervical cancer. The committee makes recommendations regarding national program goals and objectives; implementation strategies; and program priorities including surveillance, epidemiologic investigations, education and training, information dissemination, professional interactions and collaborations, and policy.

Matters To Be Discussed: The agenda will include a review and discussion of the National Breast and Cervical Cancer Early Detection Program components; professional education, screening, tracking, follow-up and case management, coalitions and partnerships, quality assurance and improvement, public education and outreach; update of the implementation of the treatment act; review of program announcement 2060, the National Cancer Prevention and Control Program; and discussion and review of related policies and emerging issues.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Debra Younginer, Executive Secretary, BCCEDCAC, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop K-57, Chamblee, Georgia 30316, Telephone: 770–488–1074.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 24, 2003.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 03–24676 Filed 9–29–03; 8:45 am] **BILLING CODE 4163–18–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee for Injury Prevention and Control

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee and committee meetings.

Name: Science and Program Review Subcommittee (SPRS), meetings of the Advisory Committee for Injury Prevention and Control, and its subcommittees, the Science and Program Review Subcommittee and the Subcommittee on Intimate Partner Violence and Sexual Assault.

Time and Date: 8 a.m.-10:15 a.m., November 5, 2003.

Place: The Westin Atlanta North at Perimeter, 7 Concourse Parkway, Atlanta, Georgia 30328.

Status: Open to the public, limited only by the space available.

Purpose: The SPRS provides advice on the needs, structure, progress and performance of programs of the National Center for Injury Prevention and Control (NCIPC), as well as second-level scientific and programmatic review for applications for research grants, cooperative agreements, and training grants related to injury control and violence prevention, and recommends approval of projects that merit further consideration for funding support. The SPRS also advises on priorities for research to be supported by contracts, grants, and cooperative agreements and provides concept review of program proposals and announcements.

Matters to be Discussed: The SPRS will discuss the new research agenda, upcoming program announcements and meeting dates.

Name: Subcommittee on Intimate Partner Violence and Sexual Assault (SIPVSA). Time and Date: 8:30 a.m.-10:15 a.m.,

November 5, 2003.

Place: The Westin Atlanta North at Perimeter, 7 Concourse Parkway, Atlanta, Georgia 30328.

Status: Open to the public, limited only by the space available.

Purpose: To advise and make recommendations to the full advisory committee and the Director, NCIPC, regarding feasible goals for prevention and control of domestic and sexual violence. The SIPVSA will make recommendations regarding strategies, objectives, and priorities in programs, policies and research, and will also review the NCIPC research agenda priorities and implementation related to intimate partner violence and sexual assault.

Matters to be Discussed: The SIPVSA will hold a conference call meeting to discuss strategies for examining models for integration of intimate partner violence and sexual assault prevention into broader public health infrastructure and strategies.

Place: The Westin Atlanta North at Perimeter, 7 Concourse Parkway, Atlanta, Georgia 30328.

Status: Open to the public, limited only by the space available.

Name: Advisory Committee for Injury Prevention and Control.

Time and Dates:

1 p.m.-5:45 p.m., November 5, 2003. 8:30 a.m.–2:30 p.m., November 6, 2003.

Place: The Westin Atlanta North at Perimeter, 7 Concourse Parkway, Atlanta, Georgia 30328.

Status: Open to the public, limited only by the space available.

Purpose: The Committee advises and makes recommendations to the Secretary, Health and Human Services, the Director, CDC, and the Director, NCIPC, regarding feasible goals for the prevention and control of injury. The Committee makes recommendations regarding policies, strategies, objectives, and priorities, and

reviews progress toward injury prevention and control.

Matters to be Discussed: Prior to the full committee meeting, there will be a brief meeting conducted by conference call of the Working Group on Injury Control and Infrastructure Enhancement, a group formed to report to the full committee identifying gaps and suggesting ways to enhance injury prevention efforts. The working group will focus on defining injury infrastructure and developing a simple mechanism to assess current efforts underway throughout the injury field to enhance that infrastructure. Starting at 1 p.m., the full committee will meet. Agenda items include an update on Center activities from the Director, NCIPC; discussion of results of DHHS' review of the Federal Advisory Committee survey results of ACIPC; reports from the Subcommittees and Working Group; state infrastructure development; an introduction to CDC's Injury Research Agenda charge to the Committee update of research implementation and evaluation, review of plans for updating the research agenda; and ways of ensuring the translation of research into practice; updating the acute care agenda; NCIPC injury prevention recommendations, CDC's Strategic Initiative; and implementation of the President's Management Agenda at CDC.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Ms. Louise Galaska, Executive Secretary, ACIPC, NCIPC, CDC, 4770 Buford Highway, NE, M/S K02, Atlanta, Georgia 30341-3724, telephone (770) 488-4694.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 24, 2003.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 03-24673 Filed 9-29-03; 8:45 am] BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND **HUMAN SERVICES**

Centers for Disease Control and Prevention

Candidate Chemicals for Possible Inclusion in Future Releases of the National Report on Human Exposure to **Environmental Chemicals**

AGENCY: Centers for Disease Control and Prevention (CDC), Health and Human Services (HHS).

ACTION: On Monday, October 7, 2002, CDC published final selection criteria and solicited nominations for chemicals or categories of chemicals for analytical development and inclusion in future

releases of the National Report on Human Exposure to Environmental Chemicals (the "Report"). (See 67 FR, p. 62477-8, October 7, 2002.) Subsequently, the nominated chemicals were published on CDC's Web site, http://www.cdc.gov/exposurereport. CDC now provides the list of candidate chemicals by priority groups that may be included in future releases of the "Report." Using the selection criteria and the weighting factors described in the above-mentioned notice, an expert panel of outside reviewers and scientists at CDC's National Center for Environmental Health, Division of Laboratory Sciences, scored nominated individual chemicals or categories of chemicals. On the basis of their final point score, chemicals were placed in one of five priority groups. Listing these chemicals or categories of chemicals in priority groups does not imply that CDC has determined that exposure to them causes adverse human health effects. The nominations enabled CDC to learn which chemicals or categories concerned the public and the scientific community. Chemicals in the priority groups are listed in alphabetical order. Chemicals in Group 1 are more likely, but not guaranteed, to appear in future releases of the "Report" than are chemicals in the remaining groups. In addition to appearing in the Federal **Register**, the list of candidate chemicals will appear on CDC's Web site at http:/ /www.cdc.gov/exposurereport/ candidatechemicals. CDC will publish additional notices in the Federal **Register** as needed to keep the public abreast of progress.

Candidate Chemicals in Priority Groups

Group 1 [in alphabetical order]

1.3-Butadiene

1-Decanesulfonic acid,

1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10, 10, 10heneicosafluoro, ammonium salt

Aldicarb

Benzo[a]pyrene Dichlorvos (DDVP)

Diesel exhaust

Dimethoate

Ethylene dibromide

Fonofos Formaldehyde

Isodrin

Mancozeb

Manganese

Methyl bromide

N-methyl perfluorooctanesulfonamidoacetate (M570)

Octabromodiphenyl ether (OBDE)

Pentabromodiphenyl ether (PeBDE) congeners include BDE 82, 116, and 119 Perfluorinated carboxylic acid metabolites of telomer alcohol or telomer acrylate (n = 3)Perfluorobutane sulfonate (PFBS)